GeneDx Holdings Corp. (WGS) came out with quarterly earnings of $0.28 per share, beating the Zacks Consensus Estimate of $0.11 per share. This compares to loss of $0.33 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 154.55%. A quarter ago, it was expected that this company would post earnings of $0.20 per share when it actually produced earnings of $0.70, delivering a surprise of 250%.Over the last four quarters, the company ...

Financial Performance - Total revenue for Q1 2025 was $87.115 million, a 39.7% increase from $62.422 million in Q1 2024[15] - Diagnostic test revenue reached $85.759 million, up 40.4% from $61.104 million year-over-year[15] - Gross profit for Q1 2025 was $58.476 million, compared to $37.411 million in Q1 2024, reflecting a gross margin improvement[15] - The net loss for Q1 2025 was $6.529 million, significantly reduced from a net loss of $20.239 million in Q1 2024[15] - Revenue from patients with third-party insurance was $68.059 million for the three months ended March 31, 2025, up from $43.839 million in the same period of 2024, reflecting a growth of about 55.2%[39] - Revenue for the GeneDx segment was $87.1 million for the three months ended March 31, 2025, an increase from $62.4 million in the same period of 2024, reflecting a growth of approximately 39.6%[109] - For the three months ended March 31, 2025, the net loss attributable to common stockholders was $6.5 million, compared to a net loss of $20.2 million for the same period in 2024, resulting in a basic and diluted loss per share of $0.23, down from $0.78[104] Assets and Liabilities - Cash and cash equivalents increased to $99.704 million as of March 31, 2025, up from $85.212 million at the end of 2024[14] - Total assets grew to $446.430 million, an increase from $419.380 million at the end of 2024[14] - The company recorded a total financial liability of $4.619 million as of March 31, 2025, compared to $3.519 million as of December 31, 2024, indicating an increase of approximately 31.4%[47] - The Company reported total liabilities of $41.9 million as of March 31, 2025, compared to $30.0 million as of December 31, 2024, reflecting an increase of approximately 39.6%[106] Operational Performance - The company reported a loss from operations of $4.551 million for Q1 2025, an improvement from a loss of $13.660 million in Q1 2024[15] - Research and development expenses were $12.577 million, compared to $11.567 million in the same period last year[15] - The company has established liabilities of $14.0 million and $12.6 million for potential recoupments of payments as of March 31, 2025, and December 31, 2024, respectively[46] Strategic Initiatives - The company plans to pursue a new strategic direction and expects to scale to profitability[12] - GeneDx is in the process of acquiring Fabric Genomics, which is expected to enhance its service offerings[12] - The Company entered into a merger agreement to acquire Fabric Genomics for approximately $33.0 million in cash, with potential milestone payments totaling up to $18.0 million based on revenue performance[112] Stock and Compensation - Stock-based compensation expense for the three months ended March 31, 2025, totaled $3,983 million, compared to a reversal of $451 million in the same period of 2024[86] - The Company granted 460,439 restricted stock units during the three months ended March 31, 2025, with a weighted-average grant-date fair value of $94.22[95] - Unrecognized stock-based compensation expense related to the Company's restricted stock units was $48.0 million as of March 31, 2025[97] Debt and Financing - The Company entered into the Perceptive Term Loan Facility on October 27, 2023, with an initial tranche of $50 million funded and an additional tranche of $25 million available until December 31, 2024[68] - The Perceptive Term Loan Facility has a maturity date of October 27, 2028, with an interest rate of Term SOFR plus an applicable margin of 7.5%[70] - The Company made principal payments totaling $0.3 million during the three months ended March 31, 2025, with an outstanding loan balance of $5.5 million from the DECD Loan Agreement[77] Tax and Regulatory Matters - The effective tax rate for the three months ended March 31, 2025, was (1.2)%, compared to 0.4% for the same period in 2024, primarily due to changes in valuation allowances related to deferred tax assets[102] - The company plans to adopt ASU 2023-09 regarding income tax disclosures in its Annual Report for the year ended December 31, 2025, without expecting a material impact on its consolidated financial statements[36] - The company is currently evaluating the impact of ASU 2024-03 on its consolidated financial statements, which requires additional disclosures about specific expense categories[38]

Revenue Growth - First quarter 2025 revenues reached $87.1 million, reflecting a 42% year-over-year increase[5] - Exome and genome test revenue grew to $71.4 million, marking a 62% year-over-year growth[5] - Total revenue for the three months ended March 31, 2025, reached $87,115,000, compared to $62,422,000 in the prior year, marking a year-over-year increase of 39.6%[26] - Diagnostic test revenue for the three months ended March 31, 2025, was $85,759,000, an increase from $61,104,000 in the same period of 2024, representing a growth of 40.3%[26] Profitability and Loss - Adjusted net income for the first quarter 2025 was $7.7 million, compared to an adjusted net loss of $8.0 million in the same quarter of 2024[6] - The net loss for the three months ended March 31, 2025, was $6,529,000, a significant reduction from a net loss of $20,239,000 in the prior year, indicating a decrease in losses by 67.7%[26] - The company reported a loss from operations of $4,551,000 for the three months ended March 31, 2025, a significant improvement from a loss of $13,660,000 in the same period of 2024[26] Margin Improvement - Adjusted gross margin improved to 69% in Q1 2025, up from 61% in Q1 2024[5] - The gross margin improved to 67.1% for the three months ended March 31, 2025, compared to 59.9% in the same period of 2024[26] Expenses - Research and development expenses for the three months ended March 31, 2025, were $12,577,000, compared to $11,567,000 in 2024, representing an increase of 8.7%[26] - Selling and marketing expenses increased to $18,316,000 for the three months ended March 31, 2025, from $16,085,000 in the same period of 2024, a rise of 13.8%[26] - General and administrative expenses rose to $32,134,000 for the three months ended March 31, 2025, compared to $23,419,000 in 2024, reflecting an increase of 37.1%[26] Cash Position - Cash position as of March 31, 2025, was $160.2 million, including $4.1 million generated from ordinary operations[10] - Cash and cash equivalents increased to $99,704,000 as of March 31, 2025, up from $85,212,000 at the end of December 2024, indicating a growth of 17.0%[24] - Cash, cash equivalents, and restricted cash at the end of the period totaled $100.694 million, up from $84.660 million at the end of March 2024[28] Strategic Initiatives - GeneDx plans to acquire Fabric Genomics, expected to contribute $3 to $5 million in post-close revenue[10] - GeneDx launched ultraRapid Whole Genome Sequencing, providing genomic insights in as soon as 48 hours for neonatal and pediatric patients[10] - The company expanded its commercial footprint with new indications for cerebral palsy and Inborn Errors of Immunity, enhancing access to genomic testing[10] Investment and Financing - The company invested $6.129 million in property and equipment, compared to $443,000 in the same period last year[28] - Proceeds from offerings, net of issuance costs, amounted to $13.894 million, with no such proceeds reported in the same quarter of 2024[28] - Cash paid for interest decreased to $1.600 million from $2.019 million year-over-year[28] Cash Flow - Net cash provided by operating activities was $10.182 million, compared to a net cash used of $16.413 million in the prior year[28] - The company had a net cash used in investing activities of $9.408 million, contrasting with a net cash provided of $843,000 in the prior year[28] - The change in accounts receivable was a negative $8.557 million, indicating a decrease in cash flow from sales[28]

GeneDx Holdings Corp. (WGS) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock prices -- has triggered this rating change.The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the system. ...

Analyst’s Disclosure: I/we have a beneficial long position in the shares of WGS either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Although there are no personal account positions, SOME STOCKS MENTIONED CAN ALREADY BE PART OF THE PORTFOLIOS OF FAMILY AND ASSOCIATES and reti ...

GeneDx Holdings Corp. (WGS) is slated to report its first-quarter 2025 results on April 30, before the market opens.The renowned genetic testing company reported adjusted earnings of 70 cents per share in the last reported quarter, topping the Zacks Consensus Estimate by a staggering 250%. GeneDx surpassed estimates in each of the trailing four quarters, the average surprise being 120.05%. (Find the latest EPS estimates and surprises on Zacks Earnings Calendar.)WGS’ Q1 EstimatesThe Zacks Consensus Estimate ...

Michael Wiggins De Oliveira is an inflection investor. This means buying into cheap companies at the moment when their narrative is changing and the business is on a path toward becoming significantly more profitable over the next year.With a focus on tech and “the Great Energy Transition (including uranium)”, Michael runs a concentrated portfolio with approximately 15 to 20 stocks and an average holding period of 18 months. Through his 10+ years analyzing countless companies, Michael has accumulated outsta ...

NEW YORK, March 3, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  GeneDx Holdings Corp ("GeneDx" or the "Company") (NASDAQ: WGS). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.The investigation concerns whether GeneDx and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the class action]On February 5, 2025, Gri ...

Investors might want to bet on GeneDx Holdings Corp. (WGS) , as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______ to _______ Commission file number 001-39482 GeneDx Holdings Corp. (Exact name of registrant as specified in its charter) Delaware 85-1966 ...